Rocío López Mármol

Rocío López Mármol

Auto-generated profile, based on publicly available information

Rocío López Mármol

Department of Obstetrics and Gynecology Hospital Universitario Virgen de las Nieves Granada Spain

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 February 2026 in Ultrasound in Obstetrics & Gynecology
Verified
Journal Article
Closed access
RLR. López‐Mármol
R. López‐Mármol
José Alejandro Ávila CabrejaJosé Alejandro Ávila Cabreja
José Alejandro Ávila Cabreja
OOOlga Ocón-Hernández
Olga Ocón-Hernández
OVOtilia Ruth Gonzalez Vanegas
Otilia Ruth Gonzalez Vanegas
FFF. Figueras
F. Figueras
Francisca MolinaFrancisca Molina
Francisca Molina

23 July 2025 in Acta Obstetricia et Gynecologica Scandinavica
Verified
Journal Article
Open access
RMRocío López Mármol
Rocío López Mármol
JCJosé Alejandro Ávila Cabreja
José Alejandro Ávila Cabreja
THTeresa De Haro-Romero
Teresa De Haro-Romero
Catalina De Paco MatallanaCatalina De Paco Matallana
Catalina De Paco Matallana
OOOlga Ocón-Hernández
Olga Ocón-Hernández
FMFrancisca S. Molina
Francisca S. Molina
Introduction: Our objective was to compare the predictive performance of the Fetal Medicine Foundation (FMF) competing‐risk model for preterm preeclampsia (PE) screening using placental growth factor (PlGF) measurements obtained at 11–13+6 weeks versus before 11 weeks of gestation.Material and Methods: This multicenter prospective cohort study included women with singleton pregnancies attending their routine first‐trimester assessment (11+0 to 13+6 weeks) in four hospitals across Spain from 2021 to 2023. Maternal characteristics, biophysical parameters (mean arterial pressure and uterine artery pulsatility index), and biochemical markers (PlGF measured twice in each woman, before 11 weeks and between 11 and 13+6 weeks) were assessed. Risk assessment for preterm PE was estimated by the FMF algorithm. Predictive performance was evaluated by comparing detection rates (DR) at different fixed screen‐positive rates (SPR), area under the receiver‐operating characteristic curve (AUROC), and calibration plots. Statistical adjustments were made to account for prophylactic aspirin use.Results: The study population comprised 3448 women, including 19 (0.55%) who developed preterm preeclampsia and 47 (1.36%) who developed term preeclampsia. At 10% SPR, the detection rates (adjusted for aspirin use) were highest for the model incorporating PlGF between 11 and 13+6 weeks (72.9%; 95% CI, 42.2%–90.9%), compared to models with PlGF before 11 weeks (66.4%; 95% CI, 39.9%–85.4%) and without PlGF (66.0%; 95% CI, 39.3%–85.3%). Similar trends were observed at higher SPR thresholds. The best discrimination (AUROC: 0.863; 95% CI, 0.754–0.971) and calibration were also achieved by the model using PlGF between 11 and 13+6 weeks.Conclusions: PlGF measured before 11 weeks did not improve preterm PE screening performance. Due to the small number of cases, further validation is needed. Maternal and biophysical markers remain a viable alternative when PlGF is unavailable.